OXiGENE Awarded $733K in Tax Credit Grants
November 03, 2010 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISO, Calif., Nov. 3, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc., (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Third Quarter 2010 Earnings Conference Call and Webcast
October 29, 2010 18:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
Ongoing Analyses of Randomized Phase 2/3 ATC Data, Including Subgroup Analyses, Continue to Show ZYBRESTAT(TM) (CA4P) Improves Overall Survival in Patients With Anaplastic Thyroid Cancer (ATC)
October 11, 2010 06:30 ET
|
Mateon Therapeutics
Additional Data Show Survival Benefit in Both Pre-Treated (Surgery, Radiation, Chemotherapy) as well as Previously Untreated Patients
Overall Survival Was Significantly Longer in Patients Less...
ZYBRESTAT(TM) (CA4P) Improves Overall Survival in a Phase 2/3 Trial (FACT Study) of Patients With Anaplastic Thyroid Cancer (ATC)
September 12, 2010 08:45 ET
|
Mateon Therapeutics
Median Overall Survival of Patients Receiving ZYBRESTAT Plus Chemotherapy was 5.1 Months, Compared With 4.1 Months for Patients Receiving Chemotherapy Alone
Patients Alive at One-Year More Than...
OXiGENE Reports Second Quarter 2010 Financial Results
August 12, 2010 16:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 12, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc., (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Second Quarter 2010 Earnings Conference Call and Webcast
August 06, 2010 16:30 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., Aug. 6, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Announces Clinical Data From FACT Study to be Presented at the 14th International Thyroid Congress
June 24, 2010 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 24, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Presents Encouraging Preclinical Data on ZYBRESTAT Ophthalmology Program
June 22, 2010 02:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 22, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Completes Enrollment of ZYBRESTAT Phase 2 Trial in Non-Small Cell Lung Cancer
June 16, 2010 08:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 16, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
OXiGENE Reports Positive Data From Phase 1 Study of OXi4503 at the 2010 ASCO Annual Meeting
June 07, 2010 09:00 ET
|
Mateon Therapeutics
SOUTH SAN FRANCISCO, Calif., June 7, 2010 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...